Shots:
Rick and John spoke about the trial design and the results from the P-II OraGrowtH210 Trial and P-II OraGrowtH212 trial evaluating LUM-201 to treat pediatric growth hormone deficiency
They also elaborated on the timeline of the further clinical development of LUM-201
The interview gives an understanding of Lumos Pharma’s vision to develop new therapies…
Shots:
In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysis
Like any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…
The 10th Anniversary of the Pharmacovigilance Conference organized by DIA will be held from 25-26th May 2023 at Radisson Blu International Airport, Mumbai. The featured exhibitors for the conference are Parexel, Syneos Health, and Labcorp.
The conference will bring to you key speakers across the industry sharing insights on the changing PV landscape, expanding the vistas…
Shots:
In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers
Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc.
PharmaShots…
Shots:
The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month
Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs
The report summarizes the key features of Darzalex including revenue…
Active Ingredient: dulaglutide
Dosage Forms & Strengths:
Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen
Mechanism of Action: GLP-1 receptor agonist
First Approval: US (Sep 18, 2014), EU (Nov 25, 2014)
Revenue Analysis1
Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…
Shots:
Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance
Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why the DTx devices do not fit in the standards for medical devices by quoting some examples …
Shots:
Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials
She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…
Active Ingredient: Ibrutinib
Dosage Forms & Strengths:
Capsules: 70 mg and 140 mg
Tablets: 140 mg, 280 mg, 420 mg, and 560 mg
Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)
First Approval: US (13 Nov 2013), EU (Oct 2014)
Revenue Analysis
Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…
Active Ingredient: Nivolumab
Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial
Dosage Form: Injection
Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)
First Approval: US (22 Dec 2014), EU (19 Jun 2015)
Revenue Analysis of Opdivo
BMS’ Opdivo gives tough competition to other drugs in the…

